Why Atorvastatin-Calcium-Trihydrat (Ph.Eur.) is in shortage
causes not stated by the regulator
— e.g. “Erhöhte Nachfrage” (Germany)
manufacturing problems — e.g. “Probleme in der Herstellung” (Germany)
Frequently asked questions
Is Atorvastatin-Calcium-Trihydrat (Ph.Eur.) currently in shortage?
Yes. As of the latest regulator updates, Atorvastatin-Calcium-Trihydrat (Ph.Eur.) has 11 active shortage notices across 1 country (Germany). Status is refreshed daily from official regulatory sources.
Why is Atorvastatin-Calcium-Trihydrat (Ph.Eur.) in shortage?
Regulators attribute the current Atorvastatin-Calcium-Trihydrat (Ph.Eur.) shortages to causes not stated by the regulator, manufacturing problems. The exact cause varies by country and product — each notice on this page links to the official source.
When will the Atorvastatin-Calcium-Trihydrat (Ph.Eur.) shortage be resolved?
Regulator-estimated resolution dates currently range from 30 Jun 2026 to 31 Dec 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Where does this Atorvastatin-Calcium-Trihydrat (Ph.Eur.) shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Data on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.